HDAC9 and glioblastoma: Taken together, our data suggest that targeting PI3K and mTOR pathway, ligand-independent modulation using an inhibitor of HSP90, or epigenetic modulation through inhibition of HDAC could be potential strategies to improve the therapeutic outcome of GBM.